# Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer

> **NCT03692663** · EARLY_PHASE1 · UNKNOWN · sponsor: **Allife Medical Science and Technology Co., Ltd.** · enrollment: 9 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** TABP EIC
- **BIOLOGICAL:** Cyclophosphamide
- **BIOLOGICAL:** fludarabine

## Key facts

- **NCT ID:** NCT03692663
- **Lead sponsor:** Allife Medical Science and Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-01
- **Primary completion:** 2023-06
- **Final completion:** 2024-06
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2022-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03692663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03692663, "Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03692663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*